Home › Funds › Boston Trust Walden Corp › GMED
Boston Trust Walden Corp position in GMED
GLOBUS MED INC · Health Care
Boston Trust Walden Corp reported holding 1,643,143 shares of GMED (GLOBUS MED INC) in its Q3 2026 13F filing — a position valued at US$123.1M, representing 0.99% of its reported portfolio and ranking #16 among its reported holdings. Boston Trust Walden Corp has disclosed GMED holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Boston Trust Walden Corp's GMED position evolved
Boston Trust Walden Corp first disclosed a stake in GMED in Q3 2023 at 747,848 shares (US$37.1M). The position peaked in Q2 2026 at 1,573,361 shares, worth US$124.3M. Across 11 filings, Boston Trust Walden Corp increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,643,143 shares valued at US$123.1M — an increase of 69,782 shares quarter over quarter.. Notable position changes include a 25% increase in Q2 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 747.85K | $37.13M | New |
| Q4 2023 | 750.02K | $39.97M | Hold |
| Q1 2024 | 748.74K | $40.16M | Hold |
| Q2 2024 | 748.13K | $51.24M | Hold |
| Q3 2024 | 729.92K | $52.22M | Reduce |
| Q4 2024 | 619.65K | $51.25M | Reduce |
| Q3 2025 | 1.19M | $67.89M | New |
| Q4 2025 | 1.37M | $119.44M | Add |
| Q1 2026 | 1.25M | $108.12M | Reduce |
| Q2 2026 | 1.57M | $124.31M | Add |
| Q3 2026 | 1.64M | $123.07M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GMED and 13F data
GMED (GLOBUS MED INC) is a Health Care company. 35 other funds we track also report a position in GMED — the largest reported positions include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (US$338.1M), Sculptor Capital LP (US$237.0M), GW&K Investment Management, LLC (US$110.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GMED
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4.28M sh · $338.14M · Q2 2026
- Sculptor Capital LP 3.00M sh · $237.03M · Q2 2026
- GW&K Investment Management, LLC 1.47M sh · $110.29M · Q3 2026
- GENEVA CAPITAL MANAGEMENT LLC 1.25M sh · $93.58M · Q3 2026
- Madison Avenue Partners, LP 935.22K sh · $73.89M · Q2 2026
More on Boston Trust Walden Corp
FAQ
How long has Boston Trust Walden Corp held GMED?
Boston Trust Walden Corp has disclosed GMED holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is Boston Trust Walden Corp's current position in GMED?
As of Q3 2026, Boston Trust Walden Corp holds 1.64M shares of GMED (GLOBUS MED INC), valued at $123.07M, representing 0.99% of its reported portfolio and ranking #16.
Has Boston Trust Walden Corp been buying or selling GMED?
In the latest 13F filing (Q3 2026), Boston Trust Walden Corp increased its position in GMED. The position peaked in Q2 2026 at 1.57M shares.
Which other funds hold GMED?
Other major institutional holders of GMED include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC, Sculptor Capital LP, GW&K Investment Management, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.